Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy naïve Metastatic Melanoma
Stopped Strategic decision not to proceed with the opening of this study. There are no concerns over the safety or quality of the investigational products involved.
Conditions
Interventions
- DRUG: Abraxane
- DRUG: Abraxane
Sponsor
Celgene Corporation